Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.

Austin M, O'Connor S, Morilla R, Pawlyn C, Kaiser MF, Boyd KD.

Int J Lab Hematol. 2019 Sep 20. doi: 10.1111/ijlh.13112. [Epub ahead of print] No abstract available.

PMID:
31539199
2.

Physicians, paraproteins and progress: diagnosis and management of myeloma.

Pawlyn C, Jackson GH.

Br J Hosp Med (Lond). 2019 Feb 2;80(2):91-98. doi: 10.12968/hmed.2019.80.2.91.

PMID:
30746991
3.

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.

Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, Brown SR, Gregory WM, Child JA, Davies FE, Morgan GJ, Cairns DA, Jackson GH.

Lancet Haematol. 2019 Mar;6(3):e154-e166. doi: 10.1016/S2352-3026(18)30220-5. Epub 2019 Feb 6.

4.

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG.

Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7.

5.

Toward personalized treatment in multiple myeloma based on molecular characteristics.

Pawlyn C, Davies FE.

Blood. 2019 Feb 14;133(7):660-675. doi: 10.1182/blood-2018-09-825331. Epub 2018 Dec 26. Review.

6.

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group.

Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.

7.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD.

Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. No abstract available.

PMID:
30446495
8.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, Johnson D, Bertsch U, Broyl A, van Duin M, Shah R, Johansen P, Nørgaard MA, Samworth RJ, Sonneveld P, Goldschmidt H, Morgan GJ, Orfao A, Munshi N, Johnson HE, El-Galaly T, Dybkær K, Bøgsted M.

Blood Adv. 2018 Sep 25;2(18):2400-2411. doi: 10.1182/bloodadvances.2018018564. Erratum in: Blood Adv. 2019 Mar 26;3(6):874.

9.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

10.

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

Pawlyn C, Loehr A, Ashby C, Tytarenko R, Deshpande S, Sun J, Fedorchak K, Mughal T, Davies FE, Walker BA, Morgan GJ.

Leukemia. 2018 Jul;32(7):1561-1566. doi: 10.1038/s41375-018-0017-0. Epub 2018 Feb 2.

11.

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE.

Clin Cancer Res. 2018 May 15;24(10):2395-2407. doi: 10.1158/1078-0432.CCR-17-1594. Epub 2018 Feb 1.

12.

Evolutionary biology of high-risk multiple myeloma.

Pawlyn C, Morgan GJ.

Nat Rev Cancer. 2017 Aug 24;17(9):543-556. doi: 10.1038/nrc.2017.63. Review.

PMID:
28835722
13.

Neutral tumor evolution in myeloma is associated with poor prognosis.

Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF.

Blood. 2017 Oct 5;130(14):1639-1643. doi: 10.1182/blood-2016-11-750612. Epub 2017 Aug 21.

14.

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.

Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF.

Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.

15.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Blood. 2017 Jul 6;130(1):30-34. doi: 10.1182/blood-2017-03-774422. Epub 2017 Apr 21.

16.

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.

Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ.

Oncotarget. 2017 Apr 25;8(17):27854-27867. doi: 10.18632/oncotarget.15718.

17.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

18.

Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.

Tumber A, Nuzzi A, Hookway ES, Hatch SB, Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C, Szykowska A, Wu N, Bountra C, Strain-Damerell C, Burgess-Brown NA, Ruda GF, Fedorov O, Munro S, England KS, Nowak RP, Schofield CJ, La Thangue NB, Pawlyn C, Davies F, Morgan G, Athanasou N, Müller S, Oppermann U, Brennan PE.

Cell Chem Biol. 2017 Mar 16;24(3):371-380. doi: 10.1016/j.chembiol.2017.02.006. Epub 2017 Mar 2.

19.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ.

Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.

20.

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ.

Clin Cancer Res. 2016 Dec 1;22(23):5783-5794. Epub 2016 May 27.

21.

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.

Sriskandarajah P, Pawlyn C, Mohammed K, Dearden CE, Davies FE, Morgan GJ, Boyd KD, Kaiser MF.

Leuk Lymphoma. 2017 Feb;58(2):494-497. Epub 2016 Jul 20. No abstract available.

PMID:
27439571
22.

Nuances in the Management of Older People With Multiple Myeloma.

Pawlyn C, Gay F, Larocca A, Roy V, Ailawadhi S.

Curr Hematol Malig Rep. 2016 Jun;11(3):241-51. doi: 10.1007/s11899-016-0323-4. Review.

23.

The safety of pomalidomide for the treatment of multiple myeloma.

Jones JR, Pawlyn C, Davies FE, Morgan GJ.

Expert Opin Drug Saf. 2016;15(4):535-47. doi: 10.1517/14740338.2016.1154039. Epub 2016 Mar 16. Review.

PMID:
26913560
24.

Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma.

Wale A, Pawlyn C, Kaiser M, Messiou C.

Haematologica. 2016 Apr;101(4):e142-4. doi: 10.3324/haematol.2015.139816. Epub 2016 Jan 27. No abstract available.

25.

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

Pawlyn C, Fowkes L, Otero S, Jones JR, Boyd KD, Davies FE, Morgan GJ, Collins DJ, Sharma B, Riddell A, Kaiser MF, Messiou C.

Leukemia. 2016 Jun;30(6):1446-8. doi: 10.1038/leu.2015.338. Epub 2015 Dec 9. No abstract available.

26.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ.

J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17.

27.

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ.

Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997.

28.

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.

Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ.

Blood. 2015 Jan 29;125(5):831-40. doi: 10.1182/blood-2014-07-584268. Epub 2014 Nov 26.

29.

Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.

Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, Morgan GJ, Andreyev HJ.

Blood. 2014 Oct 9;124(15):2467-8. doi: 10.1182/blood-2014-06-583302. No abstract available.

PMID:
25301337
30.

A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex.

Mirabella F, Murison A, Aronson LI, Wardell CP, Thompson AJ, Hanrahan SJ, Fok JH, Pawlyn C, Kaiser MF, Walker BA, Davies FE, Morgan GJ.

PLoS One. 2014 Jun 12;9(6):e99493. doi: 10.1371/journal.pone.0099493. eCollection 2014.

31.

Current and potential epigenetic targets in multiple myeloma.

Pawlyn C, Kaiser MF, Davies FE, Morgan GJ.

Epigenomics. 2014 Apr;6(2):215-28. doi: 10.2217/epi.14.12. Review.

PMID:
24811790
32.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ.

Blood. 2014 May 29;123(22):3414-9. doi: 10.1182/blood-2013-12-542662. Epub 2014 Apr 14.

PMID:
24733348
33.

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.

Brioli A, Melchor L, Titley I, Vijayaraghavan G, Stephens C, Zeisig A, Pawlyn C, Cavo M, Morilla R, Davies FE, Morgan GJ.

Leuk Lymphoma. 2014 Nov;55(11):2665-8. doi: 10.3109/10428194.2014.900765. Epub 2014 Apr 22. No abstract available.

PMID:
24660850
34.

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

Brioli A, Boyd KD, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ.

Br J Haematol. 2013 Apr;161(2):291-4. doi: 10.1111/bjh.12218. Epub 2013 Jan 29. No abstract available.

PMID:
23356460
35.

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

Brioli A, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ.

Leuk Lymphoma. 2013 Sep;54(9):1975-81. doi: 10.3109/10428194.2012.760736. Epub 2013 Jan 23.

PMID:
23270579
36.

Understanding the molecular biology of myeloma and its therapeutic implications.

Boyd KD, Pawlyn C, Morgan GJ, Davies FE.

Expert Rev Hematol. 2012 Dec;5(6):603-17. doi: 10.1586/ehm.12.51. Review.

PMID:
23216592
37.

Crystalline keratopathy associated with monoclonal gammopathy of undetermined significance.

Nagendran ST, Pawlyn C, Brown M, Pelosini L.

Br J Haematol. 2012 Nov;159(3):258. doi: 10.1111/bjh.12047. Epub 2012 Sep 7. No abstract available.

PMID:
22957664
38.

Grading criteria.

Pawlyn C, West R.

Physiotherapy. 1978 May;64(5):151. No abstract available.

PMID:
652861

Supplemental Content

Loading ...
Support Center